# Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

> **NCT06490081** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 40 (estimated)

## Conditions studied

- Myelosuppression

## Interventions

- **DRUG:** Trilaciclib

## Key facts

- **NCT ID:** NCT06490081
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-26
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490081, "Trilaciclib Prevents Myelosuppression With Chemoradiotherapy". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06490081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*